Raxatrigine
(also known as GSK-1014802 and CNV-1014802) is a novel, potent small
molecule state-dependent sodium channel blocker, the Nav1.7 sodium
channel inhibitor. It has the potential to be used as an analgesic and
is being developed by Convergence Pharmaceuticals for the treatment of
lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).
纯度:≥98%
CAS:934240-31-0